source
- Roche reports phase 3 success for sefaxersen in IgA nephropathy, eyes accelerated approvalRoche announced that its experimental drug sefaxersen met the primary endpoint in a phase 3 trial for IgA nephropathy, showing reduced proteinuria versus placebo. The interim analysis at week 37 d…
- FDA nominee Heidi Overton pledges faster drug trials to keep US biotech competitiveHeidi Overton, President Trump's nominee for FDA commissioner, will appear before a Senate committee to outline her priorities for the agency. She said the administration wants her to 'go fast,' a…